© 2017 Pharmstandard Ventures
Allena Pharmaceuticals
Newtom, MA, USA
Year of Investment: 2014
IPO in November 2017
Newtom, MA, USA
Year of Investment: 2014
IPO in November 2017
Allena
Pharmaceuticals
Newton, MA, USA
Year of Investment: 2014
IPO in November 2017
Pharmaceuticals
Newton, MA, USA
Year of Investment: 2014
IPO in November 2017
Allena Pharmaceuticals, Inc.,is a biopharmaceuticalcompany developing innovative non-systemic enzymetherapeutics to treat metabolic and orphan diseases.Allena's lead program ALLN-177 is an orally administeredrecombinant oxalatedegradingenzyme for the management of hyperoxaluria and kidney stones(nephrolithiasis).
For more information, please visit:
www.allenapharma.com
For more information, please visit:
www.allenapharma.com
← Previous
Proteon Therapeutics
Next →
enGene
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally